- Home
- ORIC vs REAL Comparison
ORIC vs REAL Comparison
Compare ORIC & REAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORIC
- REAL
- Stock Information
- Founded
- ORIC 2014
- REAL 2011
- Country
- ORIC United States
- REAL United States
- Employees
- ORIC N/A
- REAL N/A
- Industry
- ORIC Biotechnology: Pharmaceutical Preparations
- REAL Other Specialty Stores
- Sector
- ORIC Health Care
- REAL Consumer Discretionary
- Exchange
- ORIC Nasdaq
- REAL Nasdaq
- Market Cap
- ORIC 1.1B
- REAL 1.2B
- IPO Year
- ORIC 2020
- REAL 2019
- Fundamental
- Price
- ORIC $12.96
- REAL $12.45
- Analyst Decision
- ORIC Strong Buy
- REAL Strong Buy
- Analyst Count
- ORIC 8
- REAL 5
- Target Price
- ORIC $16.57
- REAL $12.20
- AVG Volume (30 Days)
- ORIC 1.5M
- REAL 3.1M
- Earning Date
- ORIC 11-06-2025
- REAL 11-10-2025
- Dividend Yield
- ORIC N/A
- REAL N/A
- EPS Growth
- ORIC N/A
- REAL N/A
- EPS
- ORIC N/A
- REAL N/A
- Revenue
- ORIC N/A
- REAL $636,971,000.00
- Revenue This Year
- ORIC N/A
- REAL $14.56
- Revenue Next Year
- ORIC N/A
- REAL $10.14
- P/E Ratio
- ORIC N/A
- REAL N/A
- Revenue Growth
- ORIC N/A
- REAL 12.68
- 52 Week Low
- ORIC $3.90
- REAL $2.81
- 52 Week High
- ORIC $14.93
- REAL $12.81
- Technical
- Relative Strength Index (RSI)
- ORIC 53.61
- REAL 67.04
- Support Level
- ORIC $11.71
- REAL $12.11
- Resistance Level
- ORIC $13.80
- REAL $12.81
- Average True Range (ATR)
- ORIC 0.69
- REAL 0.61
- MACD
- ORIC -0.11
- REAL 0.09
- Stochastic Oscillator
- ORIC 50.63
- REAL 87.64
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
About REAL The RealReal Inc.
The RealReal is the largest pure-play luxury resale platform in the US, generating $1.8 billion in 2024 gross merchandise volume and addressing a niche (personal luxury resale) that had previously been serviced by inefficient upscale boutiques and local pawn shops. The company generates revenue via consignment and first-party sales on its online marketplace, and through a small volume of direct sales. With a hands-on approach that actively sources inventory and authenticates every item on its platform, The RealReal is able to justify much higher take rates than peers, working out to roughly 36% of net merchandise value in 2024, which excludes returns, cancellations, and first-party sales.